Assembly Biosciences Reports Interim Phase 1a Results From Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366; Says ABI-5366 Was Well Tolerated, Half-Life Of ~20 Days Supports Once-Weekly Or Once-Monthly Oral Dosing
Portfolio Pulse from Benzinga Newsdesk
Assembly Biosciences announced interim results from a Phase 1a trial for their helicase-primase inhibitor candidate, ABI-5366. The drug was well tolerated and has a half-life of approximately 20 days, supporting potential once-weekly or once-monthly oral dosing.
September 23, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Assembly Biosciences' interim Phase 1a trial results for ABI-5366 show the drug is well tolerated with a long half-life, indicating potential for convenient dosing schedules.
The positive interim results for ABI-5366 suggest potential for successful development, which could enhance Assembly Biosciences' product portfolio and market position. The well-tolerated nature and long half-life of the drug are favorable for patient compliance and marketability, likely boosting investor confidence and stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100